NorthRock Partners LLC Boosts Holdings in Insulet Corporation $PODD

NorthRock Partners LLC increased its stake in shares of Insulet Corporation (NASDAQ:PODD) by 13.6% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 1,103 shares of the medical instruments supplier’s stock after purchasing an additional 132 shares during the period. NorthRock Partners LLC’s holdings in Insulet were worth $347,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of Insulet by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock worth $2,276,553,000 after purchasing an additional 178,976 shares during the period. American Century Companies Inc. boosted its position in shares of Insulet by 34.8% during the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock worth $302,686,000 after purchasing an additional 297,734 shares during the period. Groupama Asset Managment boosted its position in shares of Insulet by 0.4% during the 1st quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock worth $276,728,000 after purchasing an additional 3,759 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Insulet by 4.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier’s stock worth $177,096,000 after purchasing an additional 27,408 shares during the period. Finally, Federated Hermes Inc. boosted its position in shares of Insulet by 23.4% during the 1st quarter. Federated Hermes Inc. now owns 632,869 shares of the medical instruments supplier’s stock worth $166,198,000 after purchasing an additional 120,197 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on PODD shares. Jefferies Financial Group reiterated a “buy” rating on shares of Insulet in a report on Thursday, August 7th. Wells Fargo & Company increased their target price on shares of Insulet from $330.00 to $350.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. Rothschild & Co Redburn increased their target price on shares of Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. Leerink Partners increased their target price on shares of Insulet from $339.00 to $355.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Insulet in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus price target of $348.05.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $316.29 on Friday. The company’s fifty day moving average price is $325.99 and its 200 day moving average price is $301.60. Insulet Corporation has a 12 month low of $226.50 and a 12 month high of $353.50. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The firm has a market capitalization of $22.26 billion, a P/E ratio of 96.14, a P/E/G ratio of 2.61 and a beta of 1.40.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. During the same period last year, the firm posted $0.55 EPS. Insulet’s revenue for the quarter was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, sell-side analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.39% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.